Literature DB >> 11883941

Two splice variants of human PEX19 exhibit distinct functions in peroxisomal assembly.

Peter U Mayerhofer1, Tanja Kattenfeld, Adelbert A Roscher, Ania C Muntau.   

Abstract

PEX19 has been shown to play a central role in the early steps of peroxisomal membrane synthesis. Computational database analysis of the PEX19 sequence revealed three different conserved domains: D1 (aa 1--87), D2 (aa 88--272), and D3 (aa 273--299). However, these domains have not yet been linked to specific biological functions. We elected to functionally characterize the proteins derived from two naturally occurring PEX19 splice variants: PEX19DeltaE2 lacking the N-terminal domain D1 and PEX19DeltaE8 lacking the domain D3. Both interact with peroxisomal ABC transporters (ALDP, ALDRP, PMP70) and with full-length PEX3 as shown by in vitro protein interaction studies. PEX19DeltaE8 also interacts with a PEX3 protein lacking the peroxisomal targeting region located at the N-terminus (Delta66aaPEX3), whereas PEX19DeltaE2 does not. Functional complementation studies in PEX19-deficient human fibroblasts revealed that transfection of PEX19DeltaE8-cDNA leads to restoration of both peroxisomal membranes and of functional peroxisomes, whereas transfection of PEX19DeltaE2-cDNA does not restore peroxisomal biogenesis. Human PEX19 is partly farnesylated in vitro and in vivo. The farnesylation consensus motif CLIM is located in the PEX19 domain D3. The finding that the protein derived from the splice variant lacking D3 is able to interact with several peroxisomal membrane proteins and to restore peroxisomal biogenesis challenges the previous assumption that farnesylation of PEX19 is essential for its biological functionality. The data presented demonstrate a considerable functional diversity of the proteins encoded by two PEX19 splice variants and thereby provide first experimental evidence for specific biological functions of the different predicted domains of the PEX19 protein. (C)2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11883941     DOI: 10.1006/bbrc.2002.6568

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  The peroxisomal receptor Pex19p forms a helical mPTS recognition domain.

Authors:  Nicole Schueller; Simon J Holton; Krisztian Fodor; Morlin Milewski; Petr Konarev; Will A Stanley; Janina Wolf; Ralf Erdmann; Wolfgang Schliebs; Young-Hwa Song; Matthias Wilmanns
Journal:  EMBO J       Date:  2010-06-08       Impact factor: 11.598

2.  Farnesylation of pex19p is required for its structural integrity and function in peroxisome biogenesis.

Authors:  Robert Rucktäschel; Sven Thoms; Vadim Sidorovitch; Andre Halbach; Markos Pechlivanis; Rudolf Volkmer; Kirill Alexandrov; Jürgen Kuhlmann; Hanspeter Rottensteiner; Ralf Erdmann
Journal:  J Biol Chem       Date:  2009-05-18       Impact factor: 5.157

3.  Conservation of PEX19-binding motifs required for protein targeting to mammalian peroxisomal and trypanosome glycosomal membranes.

Authors:  Tracy Saveria; André Halbach; Ralf Erdmann; Rudolf Volkmer-Engert; Christiane Landgraf; Hanspeter Rottensteiner; Marilyn Parsons
Journal:  Eukaryot Cell       Date:  2007-06-22

4.  Identification of cellular proteins that interact with human cytomegalovirus immediate-early protein 1 by protein array assay.

Authors:  Francisco Puerta Martínez; Qiyi Tang
Journal:  Viruses       Date:  2013-12-31       Impact factor: 5.048

5.  Dengue and Zika Virus Capsid Proteins Contain a Common PEX19-Binding Motif.

Authors:  Mafalda A Farelo; Despoina Korrou-Karava; Katrina F Brooks; Tiffany A Russell; Kevin Maringer; Peter U Mayerhofer
Journal:  Viruses       Date:  2022-01-27       Impact factor: 5.048

6.  The Early-Acting Peroxin PEX19 Is Redundantly Encoded, Farnesylated, and Essential for Viability in Arabidopsis thaliana.

Authors:  Margaret M McDonnell; Sarah E Burkhart; Jerrad M Stoddard; Zachary J Wright; Lucia C Strader; Bonnie Bartel
Journal:  PLoS One       Date:  2016-01-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.